- Home
- BEAM vs AMPL Comparison
BEAM vs AMPL Comparison
Compare BEAM & AMPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- AMPL
- Stock Information
- Founded
- BEAM 2017
- AMPL 2012
- Country
- BEAM United States
- AMPL United States
- Employees
- BEAM N/A
- AMPL N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- AMPL EDP Services
- Sector
- BEAM Health Care
- AMPL Technology
- Exchange
- BEAM Nasdaq
- AMPL Nasdaq
- Market Cap
- BEAM 1.8B
- AMPL 1.5B
- IPO Year
- BEAM 2020
- AMPL 2021
- Fundamental
- Price
- BEAM $17.25
- AMPL $10.50
- Analyst Decision
- BEAM Strong Buy
- AMPL Buy
- Analyst Count
- BEAM 11
- AMPL 10
- Target Price
- BEAM $48.90
- AMPL $13.40
- AVG Volume (30 Days)
- BEAM 2.2M
- AMPL 951.3K
- Earning Date
- BEAM 05-06-2025
- AMPL 05-07-2025
- Dividend Yield
- BEAM N/A
- AMPL N/A
- EPS Growth
- BEAM N/A
- AMPL N/A
- EPS
- BEAM N/A
- AMPL N/A
- Revenue
- BEAM $63,578,000.00
- AMPL $306,601,000.00
- Revenue This Year
- BEAM N/A
- AMPL $11.64
- Revenue Next Year
- BEAM $6.32
- AMPL $10.90
- P/E Ratio
- BEAM N/A
- AMPL N/A
- Revenue Growth
- BEAM N/A
- AMPL 8.56
- 52 Week Low
- BEAM $13.53
- AMPL $7.37
- 52 Week High
- BEAM $35.25
- AMPL $14.88
- Technical
- Relative Strength Index (RSI)
- BEAM 42.35
- AMPL 63.48
- Support Level
- BEAM $15.51
- AMPL $9.09
- Resistance Level
- BEAM $20.90
- AMPL $9.64
- Average True Range (ATR)
- BEAM 1.32
- AMPL 0.47
- MACD
- BEAM -0.02
- AMPL 0.26
- Stochastic Oscillator
- BEAM 32.28
- AMPL 87.28
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About AMPL Amplitude Inc.
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue primarily through selling subscriptions to the platform. The company derives a majority of its revenue from the United States.